Pfizer (PFE) Tops Q2 EPS by 33c, Reaffirms FY22 Comirnaty and Paxlovid Sales Guidance

Pfizer (NYSE: PFE) reported Q2 EPS of $2.04, $0.33 better than the analyst estimate of $1.71. Revenue for the quarter came in at $27.7 billion versus the consensus estimate of $25.26 billion.

GUIDANCE:

Pfizer sees FY2022 EPS of $6.30-$6.45, versus the consensus of $6.62. Pfizer sees FY2022 revenue of $98-102 billion, versus the consensus of $103 billion.

Reaffirms 2022 Revenue Guidance for Comirnaty(1) and Paxlovid of ~$32 Billion and ~$22 Billion, Respectively, Despite Unfavorable Impacts from Foreign Exchange

For earnings history and earnings-related data on Pfizer (PFE) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Pfizer Invites Public to View and Listen to Webcast of August 4 Conference Call with Analysts
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity